Low-dose enoximone improves exercise capacity in chronic heart failure∗∗A list of the Enoximone Study Group Members and institutional affiliations is provided in the appendix.-Reference-Cited by-同舟云学术

Low-dose enoximone improves exercise capacity in chronic heart failure∗∗A list of the Enoximone Study Group Members and institutional affiliations is provided in the appendix.

Published:2000-08 Issue:2 Volume:36 Page:501-508
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Lowes Brian D,Higginbotham Michael,Petrovich Lawrence,DeWood Marcus A,Greenberg Mark A,Rahko Peter S,Dec G.William,LeJemtel Thierry H,Roden Robert L,Schleman Margo M,Robertson Alastair D,Gorczynski Richard J,Bristow Michael R

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference40 articles.

1. Tolerability and efficacy of carvedilol inpatients with New York Heart Association class IV heart failure;Macdonald;J Am Coll Cardiol,1999

2. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure;Packer;J Am Coll Cardiol,1987

3. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation (in press).

4. Pharmacologic and hemodynamic effects of combined beta-agonist stimulation and phosphodiesterase inhibition in the failing human heart;Gilbert;Chest,1995

5. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts;Movsesian;J Clin Invest,1991

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF;Circulation: Heart Failure;2022-05

2. Rise of cGMP by partial phosphodiesterase-3A degradation enhances cardioprotection during hypoxia;Redox Biology;2021-12

3. The Role of Positive Inotropic Drugs in the Treatment of Older Adults with Heart Failure and Reduced Ejection Fraction;Heart Failure Clinics;2017-07

4. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure;JACC: Heart Failure;2017-06

5. Translation of Cardiac Myosin Activation With 2-Deoxy-ATP to Treat Heart Failure Via an Experimental Ribonucleotide Reductase-Based Gene Therapy;JACC: Basic to Translational Science;2016-12